Medicare Part D paid $587.7M for drugs still labeled prescription-only
A federal audit found Medicare Part D sponsors paid $587.7 million to pharmacies for five drugs that retained prescription-only labeling more than a year after the brand-name versions became over-the-counter.
A federal watchdog found Medicare Part D sponsors made $587.7 million in ineligible payments to pharmacies for five drugs that continued to carry prescription-only labeling more than a year after the corresponding brand-name drugs switched to over-the-counter status. The audit highlights billing tied to obsolete labeling and points to potential gaps in Medicare Part D oversight.